جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

13 مُخرَج نتائج البحث عن «Placebo»

مقالوصول مفتوح20261استشهاد· Semantic Scholar

Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: a partitioned survival analysis

Health Economics Review · مجلد 16 (1)

BACKGROUND: Given the rising incidence of endometrial cancer in Saudi Arabia, the integration of high-cost therapeutics, such as dostarlimab (DSR), for primary advanced or recurrent (pA/rEC) disease necessitates rigorous economic appraisal. Therefore, this study aimed to evaluate the cost-utility of first-line dostarlimab plus carboplatin-paclitaxel (DSR + CP) versus placebo plus carboplatin-paclitaxel (PBO + CP) from the perspective of the Saudi healthcare payer. METHODS: A partitioned survival model was constructed to simulate patient prognosis across three health states: progression-free disease, progressive disease, and death. The model parameters were derived from the clinical efficacy data of the RUBY trial and the local cost inputs. The primary outcome was the incremental cost-effectiveness ratio (ICER), the robustness of which was evaluated via comprehensive deterministic and probabilistic sensitivity analyses to characterize parameter uncertainty. RESULTS: For the overall pA/rEC population, the DSR + CP regimen yielded an incremental 1.55 quality-adjusted life-years (QALYs) at an additional cost of $144,716, resulting in an ICER of $93,244 per QALY. Cost-effectiveness was more favorable in the mismatch repair deficient (dMMR) subgroup (ICER: $82,754/QALY) than in the mismatch repair proficient (pMMR) cohort (ICER: $132,571/QALY). The ICER is the most sensitive to the acquisition cost of the DSR. At a willingness-to-pay threshold of $90,000/QALY, the probability of DSR + CP being cost-effective was 83.9% for the dMMR subgroup. CONCLUSION: This economic evaluation indicates that DSR + CP constitutes a cost-effective intervention for pA/rEC within the dMMR subpopulation. These findings provide strong evidence for a tailored reimbursement policy that effectively utilizes resources by connecting clinical benefits with economic value in the management of pA/rEC.

dostarlimabendometrial cancercarboplatin-paclitaxelcost-utility analysis
مقالوصول مفتوح2026

Tavapadon in Parkinson’s disease: D1/D5 receptor pharmacology, clinical evidence, and translational perspectives

Frontiers in Aging Neuroscience · مجلد 18

Tavapadon is an oral, once-daily, non-catechol partial agonist selective for the D1 and D5 dopamine receptors and represents a mechanistically distinct option currently under clinical investigation for Parkinson disease (PD). This narrative review critically evaluates the biological rationale for D1/D5 receptor targeting, the pharmacological and preclinical development of tavapadon, and the accumulating phase 1–3 clinical evidence for its use as monotherapy in early PD and as adjunctive therapy in patients with motor fluctuations, while highlighting remaining evidence gaps and methodological limitations. A non-systematic literature search of PubMed/MEDLINE, Embase, ClinicalTrials.gov , and Scopus (through May 2026) was performed to identify representative and pivotal randomized controlled trials, pharmacokinetic/pharmacodynamic studies, and mechanistic preclinical investigations relevant to tavapadon and D1/D5 receptor agonism; this narrative approach was not intended to be exhaustive or fully reproducible in the manner of a systematic review. Mechanistically, selective stimulation of the direct striatal pathway together with submaximal intrinsic efficacy at the D1 receptor has been proposed, as a mechanistic hypothesis rather than a demonstrated clinical mechanism, to preserve antiparkinsonian benefit while limiting the receptor-signaling intensity implicated in levodopa-induced dyskinesia. In the phase 2 PARKWAY-II study and the now fully published phase 3 TEMPO-1 and TEMPO-2 trials, fixed- and flexible-dose tavapadon produced clinically meaningful improvements in MDS-UPDRS motor scores compared with placebo in early PD, and in the phase 3 TEMPO-3 trial, adjunctive tavapadon significantly increased daily good ON time and reduced OFF time in levodopa-treated patients with motor fluctuations; efficacy in all trials has been demonstrated only against placebo, with no head-to-head data against levodopa or other dopamine agonists. Adverse events were more frequent with tavapadon than placebo (approximately 72–76% versus 55% across TEMPO-2 and TEMPO-3), with nausea, headache, and dizziness the most common; no excess signal of impulse-control disorders relative to placebo was detected over the available 26–27-week controlled treatment period, and no clinically significant QTc prolongation was observed. The 58-week open-label TEMPO-4 extension, now reported in a peer-reviewed AAN abstract publication in Neurology alongside earlier interim conference data, suggests sustained benefit and a stable long-term levodopa requirement, but lacks a randomized control and cannot yet establish long-term safety superiority over existing agents. Tavapadon is a mechanistically novel candidate with preliminary evidence of efficacy; its ultimate clinical utility will depend on head-to-head trials and long-term safety data.

Parkinson's diseasedopamine D1 receptordopamine D5 receptormotor fluctuations
مقالوصول مفتوح2026

Evaluating the efficacy and safety of melatonin for sleep onset insomnia in children aged 6–12: a systematic review and meta-analysis

BMC Pediatrics

Abstract Background Melatonin is an endogenous hormone that regulates the body’s sleep-wake cycles. Due to several clinical trials, it is currently used as an exogenous supplement in pediatric patients who suffer from sleep-onset insomnia (SOI). Consequently, this systematic review and meta-analysis aimed to assess the evidence for the clinical efficacy of melatonin for SOI in children aged 6–12. Methods This systematic review and meta-analysis evaluated the efficacy and safety of Melatonin for sleep-onset insomnia in children aged 6–12 by conducting literature searches in PubMed (97), Google Scholar (111), OVID (33), and Web of Science (156) databases. We performed statistical tests using RevMan for meta-analysis. Heterogeneity was evaluated using the I2 statistic. To maintain the validity of the studies, each included study was assessed by the Cochrane Collaboration Risk of Bias (ROB) tool. The outcomes investigated were sleep onset time (SOT), sleep onset latency (SOL), total sleep time (TST), all-cause dropout rates, and adverse-event dropout rates. Results Three hundred ninety-eight records were identified, and 10 randomized clinical trials met the inclusion criteria. The results demonstrated that melatonin treatment group was associated with an earlier sleep onset time compared with placebo with a mean difference (MD) of -0.48 h (approximately 29 min earlier) (95% confidence interval [CI]: -0.93 to -0.02 h, p = 0.04). The heterogeneity between studies was moderate (I2 = 63%). On the other hand, it was noted that there has been noticed there was a remarkable reduction in sleep onset latency with melatonin compared to placebo, with an MD of -0.38 (95% CI: -0.57 to -0.20, p < 0.0001), with high heterogeneity (I2 = 82%). Conclusion Our study confirmed that melatonin has a marked effect regarding Sleep-onset insomnia in childhood. Therefore, we found there was a statistical and clinical improvement in sleep parameters such as sleep onset time (SOT) and total sleep time (TST) which demonstrated the safety and efficacy of melatonin. However, long-term efficacy and safety need to be addressed, especially in the pediatric population.

melatoninsleep onset insomniapediatric insomniachildren
مقالوصول مفتوح2026

Efficacy and Safety of Icotrokinra (an Interleukin-23 Inhibitor) in the Management of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis

JMA Journal · مجلد 9 (5) · 1397-1405

Background: Plaque psoriasis, which is a chronic immune-mediated inflammatory skin condition, significantly reduces patients' quality of life. The cytokine interleukin-23 (IL-23) is a pivotal factor in the development of psoriasis, and icotrokinra is a new oral IL-23 receptor antagonist that has shown potential effectiveness in clinical trials. The main goal of this systematic review and meta-analysis was to assess the effectiveness and safety of icotrokinra in adults and adolescents with moderate-to-severe plaque-type psoriasis. Methods: A comprehensive literature search in PubMed, ScienceDirect, and the Cochrane Library, conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards, identified randomized controlled trials that evaluated daily oral icotrokinra 200 mg versus placebo. The primary outcomes were Psoriasis Area and Severity Index (PASI) 90, Investigator's Global Assessment (IGA) 0/1, and adverse events (AEs) at 16 weeks. Risk ratios with 95% confidence intervals were summed up through a random-effects model. Results: A total of five randomized controlled trials involving 2,755 participants were included. Icotrokinra showed a significant increase in PASI 90, IGA 0/1, IGA 0, and Psoriasis Symptoms and Signs Diary 0 responses compared to placebo. The overall frequency of AEs was similar in both groups, but the rate of treatment discontinuation due to AEs was lower with icotrokinra. Conclusions: Icotrokinra is an effective and well-tolerated oral treatment for moderate-to-severe plaque psoriasis with considerable clinical and patient-reported benefits.

IL-23 inhibitorsplaque psoriasismoderate-to-severe psoriasisefficacy
مقالوصول مفتوح20252استشهاد· Semantic Scholar

Efficacy of ankle Kinesio taping on balance and functional performance in obese female collegiate students: a prospective randomized placebo-controlled trial

Frontiers in Public Health · مجلد 13 · 1631757-1631757

Objective: This study aimed to evaluate the efficacy of ankle Kinesio taping (KT) on static and dynamic balance and functional performance in obese female collegiate students. Design: This study was a prospective, randomized controlled trial. Setting: The research was conducted in outpatient physical therapy settings. Participants: A total of 40 female collegiate students, aged 18-25 years, were randomly assigned to two groups of equal size. Intervention: Group A (KT group) received KT with 75-100% tension, and group B (Placebo KT group) received placebo KT with 0% tension. KT was applied to the dominant leg in both groups for 6 weeks. Outcome measures: The primary outcome was static balance, which was measured using the single-leg stance test (SLST). The secondary outcomes were dynamic balance, assessed using the Biodex Balance System (BBS), and functional performance, which was assessed using the single-leg vertical jump test (SLVJT) and single-leg hop test (SLHT). All outcomes were assessed at baseline and after 6 weeks. Results: < 0.001) in the KT group compared to the control group after a period of 6 weeks. Conclusion: The application of a 6-week KT mechanical correction technique can improve static and dynamic balance and functional performance in obese female university students compared to the placebo group. Including KT in the treatment plan is recommended for obese women with balance and functional performance deficits. Clinical trial registration: ClinicalTrials.gov, identifier NCT06195748.

kinesio tapingankle tapingobesityfemale university students
مقالوصول مفتوح202416استشهاد· Semantic Scholar

Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study

Drug Design Development and Therapy · مجلد Volume 18 · 5239-5253

Background: Ulcerative colitis (UC) is an idiopathic chronic inflammation of colonic and rectal mucosa. The peroxisome proliferator-activated receptor α (PPARα) has been identified as having protective effects in UC. Aim: The study aimed to investigate the efficacy of fenofibrate, a PPARα agonist, in UC. Methods: A total of 70 patients with mild to moderate UC were allocated randomly and assigned to two groups (n = 35 each) from Gastroenterology Department, Faculty of Medicine, Menoufia University. The mesalamine group received a placebo along with 1 g of mesalamine three times daily, while the fenofibrate group received 1 g of mesalamine three times and fenofibrate 160 mg once daily. The study duration was for six months. A gastroenterologist assessed patients by non-invasive Partial Mayo Score (PMS) and the Inflammatory Bowel Disease Questionnaire (IBDQ) to evaluate clinical response and remission. The serum levels of silent information regulator 1 (SIRT1), NOD-like receptor protein 3 (NLRP3), and adenosine monophosphate activated protein kinase (AMPK), as well as fecal calprotectin levels were examined to determine the biological effect of fenofibrate. Results: After treatment, the fenofibrate group showed statistically significant reductions in PMS ( p = 0.044) and improved digestive domain of IBDQ ( p = 0.023). Additionally, there were significant decreases in serum NLRP3 ( p = 0.041) and fecal calprotectin ( p = 0.035), along with significant increases in SIRT1 ( p = 0.002) and AMPK ( p = 0.0003). The fenofibrate group also had higher response and remission rates compared to the mesalamine group. Conclusion: Fenofibrate may be a promising adjunct for improving clinical outcomes, quality of life, and modulating inflammation in mild to moderate patients with UC. Trial Registration Identifier: NCT05781698. Keywords: Ulcerative colitis, Fenofibrate, Mesalamine, NLRP3/AMPK, PPARα

ulcerative colitisfenofibrate5-aminosalicylic acidPPARα agonist
مقالوصول مفتوح20244استشهاد· Semantic Scholar

Competence of Combined Low Dose of Human Chorionic Gonadotropin (HCG) and Clomiphene Citrate (CC) Versus Continued CC during Ovulation Induction in Women with CC-Resistant Polycystic Ovarian Syndrome: A Randomized Controlled Trial

Medicina · مجلد 60 (8) · 1300-1300

Background and Objectives: Polycystic ovarian syndrome (PCOS) is a widespread endocrine disorder affecting 5–18% of females in their childbearing age. The aim of this study is to assess the efficacy of combining a low dosage of human chorionic gonadotropin (HCG) along with clomiphene citrate (CC) for stimulating ovulation in infertile women diagnosed with CC-resistant PCOS. Materials and Methods: A randomized controlled trial was carried out on 300 infertile CC-resistant PCOS women. All participants were assigned to two groups: the CC-HCG group and the CC-Placebo group. Subjects in the CC-HCG group were given CC (150 mg/day for 5 days starting on the 2nd day of the cycle) and HCG (200 IU/day SC starting on the 7th day of the cycle). Subjects in the CC-Placebo group were given CC and a placebo. The number of ovarian follicles > 18 mm, cycle cancellation rate, endometrial thickness, ovulation rate, clinical pregnancy rate, and occurrence of early ovarian hyper-stimulation syndrome were all outcome variables in the primary research. Results: Data from 138 individuals in the CC-HCG group and 131 participants in the CC-Placebo group were subjected to final analysis. In comparison to the CC-Placebo group, the cycle cancellation rate in the CC-HCG group was considerably lower. The CC-HCG group exhibited a substantial increase in ovarian follicles reaching > 18 mm, endometrial thickness, and ovulation rate. The clinical pregnancy rate was higher in the CC-HCG group (7.2% vs. 2.3%; CC-HCG vs. CC-Placebo). Upon adjusting for BMI and age, the findings of our study revealed that individuals in the CC-HCG group who had serum prolactin levels below 20 (ng/mL), secondary infertility, infertility duration less than 4 years, baseline LH/FSH ratios below 1.5, and serum AMH levels more than 4 (ng/mL) had a higher likelihood of achieving pregnancy. In the CC-Placebo group, there was a greater prediction of clinical pregnancy for those with serum AMH (<4), primary infertility, serum prolactin ≤ 20 (ng/mL), baseline LH/FSH < 1.5, and infertility duration < 4 years. Conclusions: The use of a small dose of HCG along with CC appeared to be an effective treatment in reducing cycle cancelation, improving the clinical pregnancy rate and ovulation rate in CC-resistant PCOS patients. The trial was registered with Clinical Trials.gov, identifier NCT02436226

polycystic ovary syndromeclomiphene citrate resistancehuman chorionic gonadotropinovulation induction
مقالوصول مفتوح2023

The Efficacy of Creatine Supplementation in Improving Cognitive Performance in Adolescents: A Phase-II, Triple-Blind, Randomized Study Protocol

Principles and Practice of Clinical Research Journal · مجلد 8 (4)

Background/Aims: Creatine supplementation has demonstrated cognitive benefits in neurodegenerative conditions, having a protective effect in the brain's function in stressful situations, with excellent safety (Watanabe et al., 2002). However, any beneficial effects on the cognitive performance of healthy adolescents underperforming in school is unknown. Our objective is to assess whether creatine supplementation improves cognitive performance in 15- to 17-year-old students with an average school grade below the 50th percentile. Methods: This will be a phase-II, triple-blinded, randomized, parallel-group, superiority, single-center trial. Students with grades below the 50th percentile in the prior semester will be enrolled and randomized to receive juice packages containing either creatine monohydrate supplementation (0.1 mg/kg/day), or placebo, for 12 weeks. The primary outcome will be the mean difference in change of Raven’s Standard Progressive Matrices (RSPM) scores from baseline to week 12 between groups. To achieve a 90% power for detecting a 3-point difference in change in the RSPM score, and accounting for drop-out, 116 participants will be included. Secondary outcomes will include the difference in processing speed (SpaceCode), working memory (SpaceMatrix), non-visual memory (backward digit span), percentage change in lean mass, and any safety events. Conclusion: To our knowledge, this will be the most comprehensive study assessing creatine supple-mentation in adolescents. This is a low-risk intervention that has been shown to improve cognitive function in other populations. This study will potentially support the widespread use of creatine supplementation in adolescents with low school performance, while having a positive impact on this population.

creatine monohydratedietary supplementationcognitive performanceadolescents
مقالوصول مفتوح20221استشهاد· Semantic Scholar

A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial

Journal of Inflammation Research · مجلد Volume 15 · 1159-1172

BACKGROUND AND PURPOSE: Irritable bowel syndrome (IBS) is defined as an association of chronic abdominal pain with bowel habit abnormalities, without clear organic dysfunction. T-type calcium channels and low-grade mucosal inflammation are linked to abdominal pain; however, medical treatments for IBS abdominal pain are largely ineffective. In this study, we investigated if pentoxifylline (PTX) and ethosuximide could potentially alleviate abdominal pain in patients with IBS treated with mebeverine. METHODS: We recruited 150 patients from Tanta University Hospital to this randomized, prospective, and double blinded study. Patients were randomly allocated to three groups (n = 50). Group 1 (mebeverine) received 135 mg mebeverine three times/day (t.i.d). Group 2 (ethosuximide group) received 135 mg mebeverine t.i.d plus 250 mg ethosuximide twice daily (b.i.d) and group 3 (PTX group) received 135 mg mebeverine t.i.d plus 400 mg PTX b.i.d. Patients were assessed by a gastroenterologist at baseline and 6 months after therapy. Serum interleukin-8 (IL-8), IL-6, tumor necrosis-α (TNF-α), fecal myeloperoxidase, and fecal neutrophil gelatinase associated lipocalin (NGAL) levels were measured before and after therapy. The numeric pain rating scale (NRS) was also assessed before and after therapy. PRIMARY OUTCOMES: Reduced NRS scores and abdominal pain relief. SECONDARY OUTCOMES: Decreased inflammatory biomarkers. RESULTS: After 6 months, groups 2 and 3 showed a significantly greater reduction in serum IL-8, IL-6, TNF-α, fecal myeloperoxidase, and fecal NGAL levels when compared to group 1 after therapy. Both groups 2 and 3 showed significant reductions in NRS scores when compared to the group 1. CONCLUSION: Ethosuximide and PTX may be promising, novel adjunct drugs to antispasmodics for relieving abdominal pain in patients with IBS. TRIAL REGISTRATION: Identifier: NCT04217733.

irritable bowel syndromeabdominal painethosuximidepentoxifylline
مقالمفتوح (مستودع)2022

Attitude and practice of physicians in King Khalid University Hospital, regarding placebo 2021-2022

Medical Science · مجلد 26 (129) · 1-9

Background: In the developing world of medicine, placebo treatment has been viewed as a subject of controversy.Some physicians support its' use and advocate its effectiveness while others are against it for various reasons.This study provides identification of the practice of placebo and debates its validity.Methods: A cross-sectional study was conducted in King Khalid University Hospital in Riyadh-Saudi Arabia, targeting doctors from both genders different ages and experiences.190 physicians were chosen by quota sampling technique.The data was collected by a printed survey and distributed manually.SPSS software was used for analyzing.Results: The results showed that age, years of experience and the specialty of the physician doesn't influence their frequency of placebo use or the attitude.However, positive attitude prevailed more among male physicians (p=0.0204).78% of the physicians in this study had positive attitude towards placebo prescription while none showed a negative attitude.80% of residents used placebo used it to calm the patient and 35% as a treatment for nonspecific symptoms.Conclusion: Despite of the ethical controversy of prescribing placebo, a fair number of doctors prescribe it to their patients.This study revealed that there is no significant difference in age, gender, experience, or specialty between doctors who support placebo as a medical treatment compared to those who do not.Our study provides valuable data about the attitudes of physicians towards such a controversial methodology of treatment.

physician attitudesplacebo usemedical ethicsgender differences in physicians
مقالوصول مفتوح20214استشهاد· Semantic Scholar

Knowledge, Attitude, and Practice of Complementary and Alternative Medicine among Program’s Residents in Tabuk, Saudi Arabia

Open Access Macedonian Journal of Medical Sciences · مجلد 9 (E) · 150-154

BACKGROUND: Complementary and alternative medicine (CAM) focuses on stimulating the body’s ability to heal itself through energy alignment, herbal supplementation, and other balancing techniques. AIM: The objective of the study was to investigate and compare the Knowledge Attitude Practice (KAP) of CAM among program’s residents in Tabuk region. METHODS: A cross-sectional CAP study was conducted among program’s residents in Tabuk region. All program’s residents of all specialties in Tabuk region were included in the study. Data were collected by predesigned electronic questionnaire covering the needed items. Collected data were coded and analyzed using SPSS Inc., Chicago, Illinois, USA. The Chi-square test was used as a test of significance and p = 0.05 or less was considered statistically significant. RESULTS: Most (95.8%) of the participants have heard about CAM, 25% have used CAM in treatment before, and 72.3% of them reported beneficial outcome, 25.7% strongly agree and 48.6% agree that CAM is a useful complement to pharmacological medicine, 38.2% believed that the results of CAM are usually due to the placebo effect, and 52.1% recommended using CAM. On the other hand, 79.9% have knowledge about acupuncture, 54.9% spiritual healing and herbal medicine, 43.1% massage, 41% yoga, 70.8% bloodletting cupping, and 56.3% about cauterization. More than third (38.2%) of the participants agreed that the use of herbal products is a valid form of drugs which can be used for the treatment of variety of diseases, 48.6% agreed that CAM is a useful complement to pharmacological medicine, while 36.1% strongly agreed that CAM treatments are not tested in a scientifically recognized manner. CONCLUSION: In our study, the majority of program’s residents in Tabuk region agree that CAM is a useful complement to pharmacological medicine and recommended using CAM while reasonable percentage of them believed that the results of CAM are usually due to the placebo effect.

complementary and alternative medicineknowledge, attitudes and practicesmedical residentsacupuncture
مقالوصول مغلق20212استشهاد· Semantic Scholar

Retracted: Calcitonin Gene‐Related Peptide (CGRP) Antagonists: A comprehensive review of safety, efficacy and prescribing information

Journal of Clinical Pharmacy and Therapeutics · مجلد 47 (1) · i-i

WHAT IS KNOWN AND OBJECTIVES: Migraine is a disabling disorder that affects individuals of all ages. To date, there are multiple limitations to using guidelines-recommended treatments and preventive therapies. The goal of this review was to provide a comprehensive clinical review of the safety, efficacy and prescribing information of the emerging calcitonin gene-related peptide (CGRP) antagonists. Agents in this new pharmacologic class were approved by the US Food and Drug Administration (FDA) for the treatment of acute migraine attack pain and the management of episodic and chronic migraine. METHODS: A total of 12 randomized, placebo-controlled clinical trials were identified and included in the review utilizing databases such as clinicaltrial.gov, PubMed and EMBASE. The trials collectively evaluated six CGRP antagonists starting from the orally administered CGRPs such as rimegepant and ubrogepant, to the quarterly IV administered CGRP such as eptinezumab, and the monthly/quarterly subcutaneously administered agents such as erenumab, fremanezumab and galcanezumab. RESULTS AND DISCUSSION: All agents displayed significant efficacy compared with placebo, measured by reduction in mean monthly migraine days (MMD). In addition, CGRP antagonists displayed a great tolerability profile with few adverse effects. These medications were neither associated with any cardiovascular-related adverse effects, nor do they currently have specific contraindications to pre-existing cardiovascular conditions. This can present a safe alternative to a wide range of patients who cannot be appropriately treated with first-line treatments such as triptans. No treatment-related death was reported in any of the clinical trials outlined and discussed. WHAT IS NEW AND CONCLUSION: Calcitonin gene-related peptide antagonists are safe and efficacious medications both in treating acute migraine headache pain and the management of episodic and chronic migraine. Head-to-head comparative studies with current guideline-recommended treatments are needed. However, CGRP antagonists are promising agents that present an alternative solution for patients living with migraine.

calcitonin gene-related peptide antagonistsmigraineepisodic migrainechronic migraine
مقالوصول مفتوح20181استشهاد

Current management of shoulder adhesive capsulitis: a randomized, triple-blind placebo-controlled trial

International Journal of Community Medicine and Public Health · مجلد 5 (9) · 3678-3678

This review is aiming to discuss both operative and non-operative current management of this adhesive capsulitis. The present review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) declaration standards for systematic reviews. A systematic search for the terms adhesive capsulitis, frozen shoulder, glucocorticoid, non-operative operative, current management, and management of systematic review in different databases, including MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL), were searched up to March 2018 for published and unpublished studies and without language restrictions. The majority of the trials show level 2 [mid-level] evidence, positive results were found for intra-articular corticosteroid injections combined with shoulder mobility and stretching exercises are more effective in providing short-term (4-6 weeks) pain relief and improved function compared to shoulder mobility and stretching exercises alone. On the basis of current clinical evidence, this systematic review suggests that there is no strong evidence to support or refute the current practice in term of adhesive capsulitis management. As there is a need of further research in this issue and to have clear uniformed prospective about the adhesive capsulitis.

frozen shoulderintra-articular corticosteroid injectionstretchinganalgesia